熱門資訊> 正文

Beyond Air停止将NeuNOS子公司出售给XTL BiopharmPharmaceuticals

2026-03-10 19:59

Beyond Air, Inc.(XAIR) 0
Xtl生物製藥(XTLB) 0

Beyond Air (XAIR) has terminated an agreement with XTL Biopharmaceuticals to sell its majority ownership interest in NeuroNOS subsidiary
The companies had entered into a letter of intent in January 2026. The letter of intent expired on March 9, 2026, in accordance with its terms, and the parties did not enter into a definitive agreement.
XAIR +4.40% premarket to $0.8968.
Source: Press Release

More on Beyond Air

Beyond Air Q3 2026 Earnings Preview
Beyond Air appoints Dan Moorhead as CFO
Seeking Alpha’s Quant Rating on Beyond Air
Historical earnings data for Beyond Air

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。